NASDAQ:ARQT Arcutis Biotherapeutics - ARQT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.31 -0.49 (-4.54%) (As of 03/24/2023 10:56 AM ET) Add Compare Share Share Today's Range$10.29▼$10.9250-Day Range$10.80▼$17.1452-Week Range$10.29▼$27.40Volume110,339 shsAverage Volume918,048 shsMarket Capitalization$629.73 millionP/E RatioN/ADividend YieldN/APrice Target$47.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcutis Biotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside350.2% Upside$47.00 Price TargetShort InterestBearish28.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 2 Articles This WeekInsider TradingSelling Shares$537,319 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.68) to ($2.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector721st out of 989 stocksPharmaceutical Preparations Industry350th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, Arcutis Biotherapeutics has a forecasted upside of 350.2% from its current price of $10.44.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.23% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 4.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 2.2 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcutis Biotherapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for ARQT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $537,319.00 in company stock.Percentage Held by Insiders23.00% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($4.68) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcutis Biotherapeutics (NASDAQ:ARQT) StockArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comNeedham & Company LLC Cuts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $24.00March 16, 2023 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Sees Large Volume IncreaseMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 14, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)March 9, 2023 | finance.yahoo.comArcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual MeetingMarch 2, 2023 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | finance.yahoo.comInvestors in Arcutis Biotherapeutics (NASDAQ:ARQT) from three years ago are still down 40%, even after 5.0% gain this past weekMarch 1, 2023 | finance.yahoo.comQ4 2022 Arcutis Biotherapeutics Inc Earnings CallMarch 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 1, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)March 1, 2023 | finance.yahoo.comArcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateFebruary 27, 2023 | msn.comArcutis Biotherapeutics's Earnings OutlookFebruary 21, 2023 | finance.yahoo.comArcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and AdolescentsFebruary 9, 2023 | seekingalpha.comArcutis Biotherapeutics: Market Discounting Zoryve MomentumFebruary 8, 2023 | finance.yahoo.comArcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor ConferenceJanuary 17, 2023 | finance.yahoo.comArcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 MonthsJanuary 14, 2023 | finance.yahoo.comArcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque PsoriasisJanuary 5, 2023 | forbes.comArcutis BiotherapeuticsDecember 23, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Arcutis Biotherapeutics (ARQT)December 19, 2022 | finance.yahoo.comArcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of AgeDecember 12, 2022 | seekingalpha.comArcutis says second Phase 3 trial for atopic dermatitis therapy reached main goalDecember 12, 2022 | marketwatch.comArcutis: Roflumilast Hits Goals Again in Atopic Dermatitis Study >ARQTDecember 12, 2022 | finance.yahoo.comArcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and OlderDecember 5, 2022 | finance.yahoo.comArcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255December 1, 2022 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)December 1, 2022 | finance.yahoo.comMyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic DermatitisNovember 28, 2022 | finance.yahoo.comStudy Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical DermatologySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Company Calendar Last Earnings11/04/2021Today3/24/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees147Year Founded2016Price Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$57.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+335.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,460,000.00 Net MarginsN/A Pretax Margin-8,449.76% Return on Equity-134.03% Return on Assets-76.77% Debt Debt-to-Equity Ratio0.94 Current Ratio11.57 Quick Ratio11.37 Sales & Book Value Annual Sales$3.69 million Price / Sales178.77 Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book3.14Miscellaneous Outstanding Shares61,080,000Free Float47,034,000Market Cap$659.66 million OptionableNot Optionable Beta0.52 Social Links Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 55)Pres, CEO & Director Comp: $940.2kDr. Bhaskar Chaudhuri Ph.D. (Age 68)Co-Founder & Independent Director Comp: $60.58kMr. Scott L. Burrows (Age 46)CFO & Principal Accounting Officer Comp: $617.87kDr. David W. Osborne Ph.D. (Age 62)Chief Technical Officer Comp: $584.55kDr. Patrick E. Burnett M.D. (Age 51)Ph.D., Sr. VP & Chief Medical Officer Comp: $700.1kMr. Matthew Richard Moore (Age 49)Sr. VP & Chief Bus. Officer Comp: $560.07kMs. Patricia A. Turney (Age 56)Sr. VP of Operations Mr. Eric McIntyreHead of Investor RelationsMs. Courtney Barton (Age 40)VP and Chief Compliance Officer & Privacy Officer Mr. Masaru Matsuda Esq. (Age 52)J.D., Sr. VP, Gen. Counsel & Corp. Sec. More ExecutivesKey CompetitorsBelite BioNASDAQ:BLTEIDEAYA BiosciencesNASDAQ:IDYADyne TherapeuticsNASDAQ:DYNTyra BiosciencesNASDAQ:TYRATheravance BiopharmaNASDAQ:TBPHView All CompetitorsInsiders & InstitutionsTodd Franklin WatanabeSold 2,435 sharesTotal: $37,158.10 ($15.26/share)Patricia A TurneySold 831 sharesTotal: $12,681.06 ($15.26/share)Scott L BurrowsSold 291 sharesTotal: $4,440.66 ($15.26/share)Todd Franklin WatanabeSold 5,472 sharesTotal: $86,621.76 ($15.83/share)Scott L BurrowsSold 1,434 sharesTotal: $22,700.22 ($15.83/share)View All Insider TransactionsView All Institutional Transactions ARQT Stock - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price forecast for 2023? 6 analysts have issued 1 year price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price forecasts range from $24.00 to $57.00. On average, they predict the company's share price to reach $47.00 in the next year. This suggests a possible upside of 335.2% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2023? Arcutis Biotherapeutics' stock was trading at $14.80 at the start of the year. Since then, ARQT stock has decreased by 27.0% and is now trading at $10.80. View the best growth stocks for 2023 here. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.01. What ETFs hold Arcutis Biotherapeutics' stock? ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), ProShares Ultra Nasdaq Biotechnology (BIB) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. What is Arcutis Biotherapeutics' stock symbol? Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT." Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (2.88%), GW&K Investment Management LLC (2.55%), Jennison Associates LLC (2.29%), Barclays PLC (1.94%), Point72 Asset Management L.P. (1.81%) and Allspring Global Investments Holdings LLC (1.75%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcutis Biotherapeutics' stock price today? One share of ARQT stock can currently be purchased for approximately $10.80. How much money does Arcutis Biotherapeutics make? Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $659.66 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.65) on an earnings per share basis. How many employees does Arcutis Biotherapeutics have? The company employs 147 workers across the globe. How can I contact Arcutis Biotherapeutics? Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com. This page (NASDAQ:ARQT) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.